Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

telaprevir

- PMLiVE

Novo Nordisk: Strict US regulation threatens innovation

Warning from CEO Sorensen comes after Tresiba and Ryzodeg fail to win FDA approval

- PMLiVE

AbbVie gets ‘breakthrough’ status for hepatitis C regimen

Combination could be all-oral alternative to injectable interferon alpha-based therapies

Roche - Basel

Roche taps local expertise for hep C drug in China

Partners with Chinese-American biotech company Ascletis

- PMLiVE

Gilead files oral hepatitis C drug sofosbuvir in US

Could be part of first all-oral regimen for virus

- PMLiVE

BMS and Vertex partner on oral hepatitis treatment

Will investigate combination of daclatasvir and VX-135

- PMLiVE

EMA launches diabetes drugs safety review

Will investigate pancreatitis risks in two major drug classes

- PMLiVE

Takeda suspended as vice president of Japanese industry body

Mis-labelling also prompts JPMA to takes action against CMO Nihon Pharmaceutical

- PMLiVE

Black triangle monitoring warning to be used across EU

Use of symbol is part of EMA plans to strengthen pharmacovigilance

- PMLiVE

Incyte says Jakafi patient developed brain virus

Investigation to determine if myelofibrosis drug is linked to PML

- PMLiVE

FDA investigates pancreas risk of diabetes drugs

Products from Merck & Co, BMS, AZ, Novo Nordisk, Boehringer, Amylin and Takeda all involved

- PMLiVE

Pfizer drops hepatitis C candidate filibuvir

Compound was lagging behind investigational drugs from Gilead and AbbVie

- PMLiVE

UK study supports earlier narcolepsy finding with GSK’s Pandemrix

Flu vaccine linked to sleeping disorder

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links